Close

Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers Mar 2, 2022 03:19PM
Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers Mar 1, 2022 09:03PM
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion Feb 15, 2022 09:04AM
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401 Dec 14, 2021 06:59AM
Bristol Myers Squibb and Celgene Issue Notices of Redemption and Partial Redemption of Certain of Their Senior Notes at “Make Whole” Prices Feb 22, 2021 06:15PM
View Older Stories

Feb 19, 2021 05:04PM Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
Feb 18, 2021 09:29PM Bristol Myers Squibb Announces Early Participation Results and Early Settlement of Tender Offers for Up to an Aggregate Purchase Price of Up to $4.0 Billion
Feb 4, 2021 06:59AM Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
Feb 4, 2021 06:30AM Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
Dec 11, 2020 08:03AM Cipla Announces Settlement of REVLIMID® (lenalidomide) Capsules Patent Litigation
Nov 21, 2019 06:26AM Amgen (AMGN) Completes Acquisition Of Otezla, Updates Guidance
Nov 21, 2019 06:21AM Amgen Completes Acquisition Of Otezla® (apremilast)
Nov 20, 2019 04:16PM Bristol-Myers Squibb (BMY) Completes Acquisition of Celgene (CELG)
Nov 20, 2019 04:16PM Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company
Nov 18, 2019 05:12PM Exelon Corporation (EXC) to Replace Celgene (CELG) in NASDAQ-100 Index
Nov 18, 2019 05:10PM Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019
Nov 18, 2019 05:10PM Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019
Nov 15, 2019 05:57PM Bristol-Myers (BMY) Receives FTC Clearance for Celgene (CELG) Acquisition, Deal Expected to Close Next Week
Nov 15, 2019 04:55PM Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition
Nov 12, 2019 09:00AM Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Nov 8, 2019 12:33PM FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
Nov 6, 2019 09:06AM Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting
Aug 26, 2019 06:32AM Amgen (AMGN) to Acquire Otezla from Celgene (CELG) for $13.4B
Aug 26, 2019 06:30AM Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion
Aug 26, 2019 06:30AM Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
Jul 29, 2019 10:10AM Bristol-Myers Squibb (BMY) Announces European Commission Approval of Pending Acquisition of Celgene (CELG)
Jul 29, 2019 10:10AM Bristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of Celgene
Jun 24, 2019 07:02AM Bristol-Myers Squibb (BMY) is Planning Divestiture of OTEZLA to Get FTC Clearance for Celgene (CELG) Deal
Jun 24, 2019 06:59AM Bristol-Myers Squibb Provides Update on Pending Merger with Celgene
Jun 14, 2019 09:00AM Leoplus USA Wins Lyfebulb-Celgene 2019 "Addressing Unmet Needs in MS: An Innovation Challenge"
Jun 5, 2019 07:02AM Bristol-Myers Squibb (BMY) Announces Leadership Team Upon Completion of Pending Merger with Celgene (CELG)
Jun 5, 2019 06:59AM Bristol-Myers Squibb Announces Post-Closing Leadership Team
Jun 4, 2019 11:01AM Celgene (CELG) Announces Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO
Jun 4, 2019 11:00AM Celgene Announces Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO 2019
Jun 4, 2019 07:32AM Celgene (CELG), Acceleron Pharma (XLRN) Announce FDA Accepts Luspatercept BLA in Myelodysplastic Syndromes and Beta-Thalassemia
Jun 4, 2019 07:30AM Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
Jun 3, 2019 09:12AM Celgene (CELG) Updated Analysis of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses in Patients Previously Treated for Myelofibrosis with Ruxolitinib
Jun 3, 2019 09:00AM Celgene Updated Analysis of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses in Patients Previously Treated for Myelofibrosis with Ruxolitinib
Jun 3, 2019 05:54AM Celgene (CELG) Announces Data from a Phase 1/2 Clinical Study of Iberdomide (CC-220) in Combination with Dexamethasone at ASCO 2019 Meetings
Jun 2, 2019 12:45PM Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019
May 15, 2019 05:04PM Celgene to Highlight New and Updated Hematology and Oncology Clinical Data at Upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
May 10, 2019 07:30AM Lyfebulb and Celgene Announce Finalists for 2019 "Addressing Unmet Needs in MS: An Innovation Challenge"
Apr 26, 2019 07:30AM Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia
Apr 12, 2019 10:48AM Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
Apr 5, 2019 09:28AM Celgene (CELG), Acceleron Pharma (XLRN) Announce Submission of Luspatercept BLA to U.S. FDA
Apr 5, 2019 09:28AM Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA
Mar 29, 2019 01:33PM Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation
Mar 29, 2019 11:14AM Bristol-Myers Squibb (BMY) Confirms ISS and Glass Lewis Recommend Shareholders Vote for Proposed Merger with Celgene (CELG)
Mar 29, 2019 11:13AM Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote “FOR” Proposed Merger with Celgene
Mar 25, 2019 07:02AM Bristol-Myers Squibb (BMY) Board Provides Open Letter Shareholder Regarding Merger Agreement with Celgene Corp. (CELG)
Mar 25, 2019 06:59AM Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Mate
Mar 19, 2019 07:00AM Bristol-Myers Squibb (BMY) Highlights Significant Benefits of Pending Transaction with Celgene (CELG)
Mar 19, 2019 06:59AM Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene
Mar 12, 2019 04:31PM Celgene (CELG) Provides Update on ABRAXANE Combination Therapy in Treatment of Metastatic TNBC and Pancreatic Cancer
Mar 12, 2019 04:30PM Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer
View Older Stories